LifeStance Health Group (NASDAQ:LFST) Stock Rating Lowered by Wall Street Zen

LifeStance Health Group (NASDAQ:LFST) was downgraded by investment analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

Several other research analysts also recently weighed in on the stock. Zacks Research downgraded shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. The Goldman Sachs Group initiated coverage on shares of LifeStance Health Group in a research note on Friday, June 5th. They issued a “neutral” rating and a $9.00 price objective for the company. BTIG Research lifted their price objective on shares of LifeStance Health Group from $12.00 to $15.00 and gave the stock a “buy” rating in a research report on Friday. JPMorgan Chase & Co. boosted their target price on shares of LifeStance Health Group from $8.00 to $9.00 and gave the company a “neutral” rating in a research note on Thursday, May 14th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of LifeStance Health Group in a report on Wednesday, May 27th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, LifeStance Health Group presently has an average rating of “Moderate Buy” and a consensus price target of $11.50.

LifeStance Health Group Trading Up 0.8%

NASDAQ:LFST opened at $10.90 on Friday. The stock has a fifty day simple moving average of $9.33 and a 200 day simple moving average of $7.82. The firm has a market capitalization of $4.23 billion, a price-to-earnings ratio of 181.67 and a beta of 1.12. LifeStance Health Group has a 1-year low of $3.74 and a 1-year high of $11.76. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.18.

LifeStance Health Group (NASDAQ:LFST) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.03. LifeStance Health Group had a return on equity of 1.56% and a net margin of 1.55%.The firm had revenue of $403.48 million for the quarter, compared to the consensus estimate of $387.46 million. The company’s revenue was up 21.2% on a year-over-year basis. Sell-side analysts forecast that LifeStance Health Group will post 0.12 earnings per share for the current year.

Insider Buying and Selling

In other LifeStance Health Group news, Director Eric Shuey sold 243,362 shares of the stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $8.02, for a total value of $1,951,763.24. Following the completion of the sale, the director owned 867,562 shares in the company, valued at $6,957,847.24. This represents a 21.91% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Darren M. Black sold 5,899,661 shares of the stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $8.02, for a total transaction of $47,315,281.22. Following the completion of the sale, the director owned 23,310,115 shares of the company’s stock, valued at approximately $186,947,122.30. The trade was a 20.20% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 7,687,394 shares of company stock worth $63,579,701. 3.50% of the stock is owned by company insiders.

Institutional Trading of LifeStance Health Group

Several hedge funds and other institutional investors have recently modified their holdings of the company. Silversmith Partners I GP LLC purchased a new position in LifeStance Health Group in the fourth quarter valued at about $100,842,000. Vanguard Group Inc. lifted its holdings in shares of LifeStance Health Group by 21.1% during the 4th quarter. Vanguard Group Inc. now owns 17,700,041 shares of the company’s stock valued at $124,608,000 after buying an additional 3,086,506 shares during the last quarter. Jennison Associates LLC grew its stake in shares of LifeStance Health Group by 38.5% in the 1st quarter. Jennison Associates LLC now owns 10,228,801 shares of the company’s stock valued at $65,157,000 after buying an additional 2,843,388 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of LifeStance Health Group by 62.3% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,793,336 shares of the company’s stock valued at $26,363,000 after buying an additional 1,839,465 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in LifeStance Health Group by 27.2% in the third quarter. Dimensional Fund Advisors LP now owns 8,363,607 shares of the company’s stock worth $45,998,000 after buying an additional 1,790,694 shares during the last quarter. 85.50% of the stock is currently owned by hedge funds and other institutional investors.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.